Want to see STRO full AI Analyst Report?
Top Page
Sutro Biopharma
(NASDAQ:STRO)
Select Model
Select Model
Rating:42Neutral
Price Target:
$21.50
▼(-6.03% Downside)
Action:Reiterated
Date:07/21/26
STRO scores low primarily due to weak financial performance—large ongoing losses, heavy cash burn, negative equity, and a sharply contracting/volatile revenue profile. Technicals add downside pressure with a bearish trend across key moving averages and negative MACD (despite oversold readings). Valuation provides limited support because the negative P/E reflects loss-making operations and there is no dividend yield data.
Positive Factors
Proprietary cell-free protein synthesis platform
Sutro’s cell-free synthesis and site-specific conjugation is a durable technical moat for engineering ADCs and engineered antibodies. A platform-based model supports repeated program creation, faster iteration and attractive partnering/licensing economics that persist beyond short-term cycles.
Negative Factors
Large negative operating and free cash flow
Sustained ~-$152M annual cash burn is a durable constraint on operations and forces dependence on external financing or dilutive transactions. This level of negative cash flow limits the company’s ability to self-fund multiple programs and increases execution risk over the next 2–6 months without new capital or major partnership receipts.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary cell-free protein synthesis platform
Sutro’s cell-free synthesis and site-specific conjugation is a durable technical moat for engineering ADCs and engineered antibodies. A platform-based model supports repeated program creation, faster iteration and attractive partnering/licensing economics that persist beyond short-term cycles.
Read all positive factors
Sutro Biopharma (STRO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$400.51M
Dividend YieldN/A
Average Volume (3M)987.85K
Price to Earnings (P/E)―
Beta (1Y)3.62
Revenue Growth49.94%
EPS Growth44.76%
CountryUS
Employees133
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.49
Shares Outstanding16,570,438
10 Day Avg. Volume2,002,360
30 Day Avg. Volume987,852
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.74
Price to Sales (P/S)0.96
P/FCF Ratio-0.55
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$52.60Price Target Upside129.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-8.53
Revenue Forecast (FY)$44.56M
Sutro Biopharma Business Overview & Revenue Model
Company Description
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions lik...
How the Company Makes Money
Sutro Biopharma primarily generates revenue through (1) collaboration and license agreements and (2) other related research and development services performed for partners; it does not rely on recurring product sales in the way a commercial-stage ...
Sutro Biopharma Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
31
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 99.61M | 102.48M | 62.04M | 153.73M | 67.77M | 61.88M |
| Gross Profit | 98.33M | 95.16M | 54.83M | 146.91M | 59.48M | 52.11M |
| EBITDA | -106.12M | -145.65M | -180.45M | -67.92M | -105.07M | -97.56M |
| Net Income | -153.60M | -191.09M | -227.46M | -106.79M | -119.20M | -105.54M |
Balance Sheet | ||||||
| Total Assets | 241.99M | 173.83M | 387.21M | 470.74M | 406.94M | 341.41M |
| Cash, Cash Equivalents and Short-Term Investments | 202.56M | 141.43M | 316.89M | 375.62M | 334.36M | 197.94M |
| Total Debt | 13.63M | 15.67M | 23.15M | 33.63M | 55.02M | 57.37M |
| Total Liabilities | 308.88M | 306.28M | 342.61M | 321.09M | 189.90M | 88.84M |
| Stockholders Equity | -66.89M | -132.45M | 44.60M | 149.65M | 217.05M | 252.56M |
Cash Flow | ||||||
| Free Cash Flow | -152.14M | -178.93M | -194.64M | -115.93M | -4.31M | -97.00M |
| Operating Cash Flow | -151.61M | -177.23M | -191.54M | -111.62M | 3.55M | -81.68M |
| Investing Cash Flow | 16.01M | 45.01M | 218.51M | -3.92M | -35.02M | -97.31M |
| Financing Cash Flow | 103.05M | 44.00K | 94.05M | 137.55M | 48.31M | 3.26M |
Sutro Biopharma Technical Analysis
Negative
22.88
Price Trends
27.64
Negative
28.85
Negative
20.71
Positive
Market Momentum
-1.92
Positive
34.03
Neutral
16.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STRO, the sentiment is Negative. The current price of 22.88 is below the 20-day moving average (MA) of 25.85, below the 50-day MA of 27.64, and above the 200-day MA of 20.71, indicating a neutral trend. The MACD of -1.92 indicates Positive momentum. The RSI at 34.03 is Neutral, neither overbought nor oversold. The STOCH value of 16.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STRO.
Sutro Biopharma Risk Analysis
Sutro Biopharma disclosed 78 risk factors in its most recent earnings report. Sutro Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sutro Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $384.77M | -2.92 | -50.68% | ― | -12.37% | 19.59% | |
59 Neutral | $287.05M | -4.30 | -20.31% | ― | 8.21% | 21.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $269.48M | -1.41 | -33.22% | ― | 215.59% | 22.48% | |
49 Neutral | $518.11M | -2.46 | -44.39% | ― | -79.06% | -397.92% | |
43 Neutral | $133.55M | -1.00 | 65.27% | ― | 4.43% | 27.41% | |
42 Neutral | $400.51M | -1.47 | 192.77% | ― | 49.94% | 44.76% |
* Healthcare Sector Average
STRO
Sutro Biopharma
24.17
15.90
192.23%
ARVN
Arvinas Holding Company
8.03
0.50
6.64%
BCYC
Bicycle Therapeutics
3.86
-4.19
-52.05%
ADCT
ADC Therapeutics
1.05
-1.68
-61.54%
CCCC
C4 Therapeutics
3.48
1.38
65.71%
OABI
OmniAb
1.98
0.03
1.54%
Sutro Biopharma Corporate Events
Executive/Board ChangesShareholder Meetings
Sutro Biopharma Shareholders Back Board, Pay and Auditor
Positive
Jun 8, 2026
On June 5, 2026, Sutro Biopharma held its 2026 Annual Meeting of Stockholders, where shareholders elected three Class II directors, Jane Chung, Connie Matsui, and James Panek, each to serve a three-year term ending at the 2029 Annual Meeting. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.